Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation.

Ng B, Cash-Mason T, Wang Y, Seitzer J, Burchard J, Brown D, Dudkin V, Davide J, Jadhav V, Sepp-Lorenzino L, Cejas PJ.

Mol Ther Nucleic Acids. 2019 Jun 7;16:194-205. doi: 10.1016/j.omtn.2019.02.013. Epub 2019 Feb 26.

2.

Improving Drug Discovery by Nucleic Acid Delivery in Engineered Human Microlivers.

Mancio-Silva L, Fleming HE, Miller AB, Milstein S, Liebow A, Haslett P, Sepp-Lorenzino L, Bhatia SN.

Cell Metab. 2019 Mar 5;29(3):727-735.e3. doi: 10.1016/j.cmet.2019.02.003.

3.

Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.

Janas MM, Zlatev I, Liu J, Jiang Y, Barros SA, Sutherland JE, Davis WP, Liu J, Brown CR, Liu X, Schlegel MK, Blair L, Zhang X, Das B, Tran C, Aluri K, Li J, Agarwal S, Indrakanti R, Charisse K, Nair J, Matsuda S, Rajeev KG, Zimmermann T, Sepp-Lorenzino L, Xu Y, Akinc A, Fitzgerald K, Vaishnaw AK, Smith PF, Manoharan M, Jadhav V, Wu JT, Maier MA.

Nucleic Acids Res. 2019 Apr 23;47(7):3306-3320. doi: 10.1093/nar/gkz140.

4.

Systematic chemical modifications of single stranded siRNAs significantly improved CTNNB1 mRNA silencing.

Chang W, Pei Y, Guidry EN, Zewge D, Parish CA, Sherer EC, DiMuzio J, Zhang H, South VJ, Strapps WR, Sepp-Lorenzino L, Colletti SL, Stanton MG.

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4513-4517. doi: 10.1016/j.bmcl.2016.07.064. Epub 2016 Jul 28.

PMID:
27503684
5.

Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth.

Khan T, Weber H, DiMuzio J, Matter A, Dogdas B, Shah T, Thankappan A, Disa J, Jadhav V, Lubbers L, Sepp-Lorenzino L, Strapps WR, Tadin-Strapps M.

Mol Ther Nucleic Acids. 2016 Aug 2;5(8):e342. doi: 10.1038/mtna.2016.55.

6.

5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates.

Parmar R, Willoughby JL, Liu J, Foster DJ, Brigham B, Theile CS, Charisse K, Akinc A, Guidry E, Pei Y, Strapps W, Cancilla M, Stanton MG, Rajeev KG, Sepp-Lorenzino L, Manoharan M, Meyers R, Maier MA, Jadhav V.

Chembiochem. 2016 Jun 2;17(11):985-9. doi: 10.1002/cbic.201600130. Epub 2016 Apr 28.

PMID:
27121751
7.

Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability.

Metzger JM, Tadin-Strapps M, Thankappan A, Strapps WR, DiPietro M, Leander K, Zhang Z, Shin MK, Levorse J, Desai K, Xu Y, Lai K, Wu W, Chen Z, Cai TQ, Jochnowitz N, Bentley R, Hoos L, Zhou Y, Sepp-Lorenzino L, Seiffert D, Andre P.

Thromb Haemost. 2015 Jun;113(6):1300-11. doi: 10.1160/TH14-06-0505. Epub 2015 Mar 19.

PMID:
25790442
8.

Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit.

Chen Z, Luo B, Cai TQ, Thankappan A, Xu Y, Wu W, DiMuzio J, Lifsted T, DiPietro M, Disa J, Ng B, Leander K, Clark S, Hoos L, Zhou Y, Jochnowitz N, Jachec C, Szczerba P, Gindy ME, Strapps W, Sepp-Lorenzino L, Seiffert DA, Lubbers L, Tadin-Strapps M.

Mol Ther Nucleic Acids. 2015 Jan 27;4:e224. doi: 10.1038/mtna.2014.75.

9.

Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor.

Iwamoto M, Friedman EJ, Sepp-Lorenzino L, Talaty JE, Agrawal NG, Wagner JA.

Cancer Chemother Pharmacol. 2015 Feb;75(2):333-42. doi: 10.1007/s00280-014-2649-8. Epub 2014 Dec 19.

PMID:
25523287
10.

A single dose of EGLN1 siRNA yields increased erythropoiesis in nonhuman primates.

Abrams MT, Koser M, Burchard J, Strapps W, Mehmet H, Gindy M, Zaller D, Sepp-Lorenzino L, Stickens D.

Nucleic Acid Ther. 2014 Dec;24(6):405-12. doi: 10.1089/nat.2014.0495.

PMID:
25272050
11.

Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates.

Parmar RG, Poslusney M, Busuek M, Williams JM, Garbaccio R, Leander K, Walsh E, Howell B, Sepp-Lorenzino L, Riley S, Patel M, Kemp E, Latham A, Leone A, Soli E, Burke RS, Carr B, Colletti SL, Wang W.

Bioconjug Chem. 2014 May 21;25(5):896-906. doi: 10.1021/bc400527e. Epub 2014 May 5.

PMID:
24742200
12.

Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates.

Barrett SE, Burke RS, Abrams MT, Bason C, Busuek M, Carlini E, Carr BA, Crocker LS, Fan H, Garbaccio RM, Guidry EN, Heo JH, Howell BJ, Kemp EA, Kowtoniuk RA, Latham AH, Leone AM, Lyman M, Parmar RG, Patel M, Pechenov SY, Pei T, Pudvah NT, Raab C, Riley S, Sepp-Lorenzino L, Smith S, Soli ED, Staskiewicz S, Stern M, Truong Q, Vavrek M, Waldman JH, Walsh ES, Williams JM, Young S, Colletti SL.

J Control Release. 2014 Jun 10;183:124-37. doi: 10.1016/j.jconrel.2014.03.028. Epub 2014 Mar 21.

PMID:
24657948
13.

An in vivo evaluation of amphiphilic, biodegradable peptide copolymers as siRNA delivery agents.

Barrett SE, Abrams MT, Burke R, Carr BA, Crocker LS, Garbaccio RM, Howell BJ, Kemp EA, Kowtoniuk RA, Latham AH, Leander KR, Leone AM, Patel M, Pechenov S, Pudvah NT, Riley S, Sepp-Lorenzino L, Walsh ES, Williams JM, Colletti SL.

Int J Pharm. 2014 May 15;466(1-2):58-67. doi: 10.1016/j.ijpharm.2014.03.011. Epub 2014 Mar 5.

PMID:
24607208
14.

Improving the in vivo therapeutic index of siRNA polymer conjugates through increasing pH responsiveness.

Guidry EN, Farand J, Soheili A, Parish CA, Kevin NJ, Pipik B, Calati KB, Ikemoto N, Waldman JH, Latham AH, Howell BJ, Leone A, Garbaccio RM, Barrett SE, Parmar RG, Truong QT, Mao B, Davies IW, Colletti SL, Sepp-Lorenzino L.

Bioconjug Chem. 2014 Feb 19;25(2):296-307. doi: 10.1021/bc400442p. Epub 2014 Jan 10.

PMID:
24409989
15.

Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.

Shi B, Abrams M, Sepp-Lorenzino L.

J Histochem Cytochem. 2013 Dec;61(12):901-9. doi: 10.1369/0022155413503662. Epub 2013 Aug 26.

16.

Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics.

Parmar RG, Busuek M, Walsh ES, Leander KR, Howell BJ, Sepp-Lorenzino L, Kemp E, Crocker LS, Leone A, Kochansky CJ, Carr BA, Garbaccio RM, Colletti SL, Wang W.

Bioconjug Chem. 2013 Apr 17;24(4):640-7. doi: 10.1021/bc300600a. Epub 2013 Mar 25.

PMID:
23496378
17.

Quantification of Cy-5 siRNA signal in the intra-vital multi-photon microscopy images.

Chen A, Dogdas B, Mehta S, Haskell K, Ng B, Keough E, Howell B, Meacham DA, Aslamkhan AG, Davide J, Stanton M, Bagchi A, Sepp-Lorenzino L, Tao W.

Conf Proc IEEE Eng Med Biol Soc. 2012;2012:3712-5. doi: 10.1109/EMBC.2012.6346773.

PMID:
23366734
18.

Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates.

Dudkin VY, Rickert K, Kreatsoulas C, Wang C, Arrington KL, Fraley ME, Hartman GD, Yan Y, Ikuta M, Stirdivant SM, Drakas RA, Walsh ES, Hamilton K, Buser CA, Lobell RB, Sepp-Lorenzino L.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2609-12. doi: 10.1016/j.bmcl.2012.01.110. Epub 2012 Feb 9.

PMID:
22374217
19.

Pyridyl aminothiazoles as potent Chk1 inhibitors: optimization of cellular activity.

Dudkin VY, Wang C, Arrington KL, Fraley ME, Hartman GD, Stirdivant SM, Drakas RA, Rickert K, Walsh ES, Hamilton K, Buser CA, Hardwick J, Tao W, Beck SC, Mao X, Lobell RB, Sepp-Lorenzino L.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2613-9. doi: 10.1016/j.bmcl.2012.01.120. Epub 2012 Feb 7.

PMID:
22365762
20.

Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery.

Shi B, Keough E, Matter A, Leander K, Young S, Carlini E, Sachs AB, Tao W, Abrams M, Howell B, Sepp-Lorenzino L.

J Histochem Cytochem. 2011 Aug;59(8):727-40. doi: 10.1369/0022155411410885.

21.

Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape.

Bartz R, Fan H, Zhang J, Innocent N, Cherrin C, Beck SC, Pei Y, Momose A, Jadhav V, Tellers DM, Meng F, Crocker LS, Sepp-Lorenzino L, Barnett SF.

Biochem J. 2011 Apr 15;435(2):475-87. doi: 10.1042/BJ20101021.

PMID:
21265735
22.

Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.

Tao W, Mao X, Davide JP, Ng B, Cai M, Burke PA, Sachs AB, Sepp-Lorenzino L.

Mol Ther. 2011 Mar;19(3):567-75. doi: 10.1038/mt.2010.282. Epub 2010 Dec 21.

23.

Regulation of microRNA-145 by growth arrest and differentiation.

La Rocca G, Shi B, Audia A, Ferrari-Amorotti G, Mellert HS, Calabretta B, McMahon SB, Sepp-Lorenzino L, Baserga R.

Exp Cell Res. 2011 Feb 15;317(4):488-95. doi: 10.1016/j.yexcr.2010.11.010. Epub 2010 Nov 25.

PMID:
21111732
24.

Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles.

Crawford R, Dogdas B, Keough E, Haas RM, Wepukhulu W, Krotzer S, Burke PA, Sepp-Lorenzino L, Bagchi A, Howell BJ.

Int J Pharm. 2011 Jan 17;403(1-2):237-44. doi: 10.1016/j.ijpharm.2010.10.025. Epub 2010 Oct 23.

PMID:
20974237
25.

Quantitative evaluation of siRNA delivery in vivo.

Pei Y, Hancock PJ, Zhang H, Bartz R, Cherrin C, Innocent N, Pomerantz CJ, Seitzer J, Koser ML, Abrams MT, Xu Y, Kuklin NA, Burke PA, Sachs AB, Sepp-Lorenzino L, Barnett SF.

RNA. 2010 Dec;16(12):2553-63. doi: 10.1261/rna.2255810. Epub 2010 Oct 12.

26.

Expression of micro-RNA-145 is regulated by a highly conserved genomic sequence 3' to the pre-miR.

La Rocca G, Shi B, Sepp-Lorenzino L, Baserga R.

J Cell Physiol. 2011 Mar;226(3):602-7. doi: 10.1002/jcp.22368.

PMID:
20717966
27.

Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.

Tao W, Davide JP, Cai M, Zhang GJ, South VJ, Matter A, Ng B, Zhang Y, Sepp-Lorenzino L.

Mol Ther. 2010 Sep;18(9):1657-66. doi: 10.1038/mt.2010.147. Epub 2010 Jul 13.

28.

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.

Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, Watkins A, Bilodeau M, Hoffman J, Sanderson P, Hartman G, Mahan E, Prueksaritanont T, Jiang G, She QB, Rosen N, Sepp-Lorenzino L, Defeo-Jones D, Huber HE.

Cancer Biol Ther. 2010 Apr 1;9(7):493-503. Epub 2010 Apr 1.

29.

Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment.

Abrams MT, Koser ML, Seitzer J, Williams SC, DiPietro MA, Wang W, Shaw AW, Mao X, Jadhav V, Davide JP, Burke PA, Sachs AB, Stirdivant SM, Sepp-Lorenzino L.

Mol Ther. 2010 Jan;18(1):171-80. doi: 10.1038/mt.2009.208. Epub 2009 Sep 8.

30.

Growth inhibition by microRNAs that target the insulin receptor substrate-1.

La Rocca G, Shi B, Badin M, De Angelis T, Sepp-Lorenzino L, Baserga R.

Cell Cycle. 2009 Jul 15;8(14):2255-9. Epub 2009 Jul 14.

PMID:
19502786
31.

Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.

Converso A, Hartingh T, Garbaccio RM, Tasber E, Rickert K, Fraley ME, Yan Y, Kreatsoulas C, Stirdivant S, Drakas B, Walsh ES, Hamilton K, Buser CA, Mao X, Abrams MT, Beck SC, Tao W, Lobell R, Sepp-Lorenzino L, Zugay-Murphy J, Sardana V, Munshi SK, Jezequel-Sur SM, Zuck PD, Hartman GD.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1240-4. doi: 10.1016/j.bmcl.2008.12.076. Epub 2008 Dec 24.

PMID:
19155174
32.

Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides.

Sepp-Lorenzino L, Ruddy M.

Clin Pharmacol Ther. 2008 Nov;84(5):628-32. doi: 10.1038/clpt.2008.174. Epub 2008 Sep 17. No abstract available.

PMID:
18800034
33.

Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase.

Garbaccio RM, Huang S, Tasber ES, Fraley ME, Yan Y, Munshi S, Ikuta M, Kuo L, Kreatsoulas C, Stirdivant S, Drakas B, Rickert K, Walsh ES, Hamilton KA, Buser CA, Hardwick J, Mao X, Beck SC, Abrams MT, Tao W, Lobell R, Sepp-Lorenzino L, Hartman GD.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6280-5. Epub 2007 Sep 7.

PMID:
17900896
34.

Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells.

Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R.

J Biol Chem. 2007 Nov 9;282(45):32582-90. Epub 2007 Sep 7.

35.

Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.

Brnardic EJ, Garbaccio RM, Fraley ME, Tasber ES, Steen JT, Arrington KL, Dudkin VY, Hartman GD, Stirdivant SM, Drakas BA, Rickert K, Walsh ES, Hamilton K, Buser CA, Hardwick J, Tao W, Beck SC, Mao X, Lobell RB, Sepp-Lorenzino L, Yan Y, Ikuta M, Munshi SK, Kuo LC, Kreatsoulas C.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5989-94. Epub 2007 Aug 19.

PMID:
17804227
36.

Development and implementation of multiplexed cell-based imaging assays.

Howell BJ, Lee S, Sepp-Lorenzino L.

Methods Enzymol. 2006;414:284-300.

PMID:
17110198
37.

An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.

Tao W, South VJ, Diehl RE, Davide JP, Sepp-Lorenzino L, Fraley ME, Arrington KL, Lobell RB.

Mol Cell Biol. 2007 Jan;27(2):689-98. Epub 2006 Nov 13.

38.

Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors.

Huang S, Garbaccio RM, Fraley ME, Steen J, Kreatsoulas C, Hartman G, Stirdivant S, Drakas B, Rickert K, Walsh E, Hamilton K, Buser CA, Hardwick J, Mao X, Abrams M, Beck S, Tao W, Lobell R, Sepp-Lorenzino L, Yan Y, Ikuta M, Murphy JZ, Sardana V, Munshi S, Kuo L, Reilly M, Mahan E.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5907-12. Epub 2006 Sep 20.

PMID:
16990002
39.

3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.

Fraley ME, Steen JT, Brnardic EJ, Arrington KL, Spencer KL, Hanney BA, Kim Y, Hartman GD, Stirdivant SM, Drakas BA, Rickert K, Walsh ES, Hamilton K, Buser CA, Hardwick J, Tao W, Beck SC, Mao X, Lobell RB, Sepp-Lorenzino L, Yan Y, Ikuta M, Munshi SK, Kuo LC, Kreatsoulas C.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6049-53. Epub 2006 Sep 15.

PMID:
16978863
40.

Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.

Sisko JT, Tucker TJ, Bilodeau MT, Buser CA, Ciecko PA, Coll KE, Fernandes C, Gibbs JB, Koester TJ, Kohl N, Lynch JJ, Mao X, McLoughlin D, Miller-Stein CM, Rodman LD, Rickert KW, Sepp-Lorenzino L, Shipman JM, Thomas KA, Wong BK, Hartman GD.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1146-50. Epub 2005 Dec 20.

PMID:
16368234
41.

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.

Tao W, South VJ, Zhang Y, Davide JP, Farrell L, Kohl NE, Sepp-Lorenzino L, Lobell RB.

Cancer Cell. 2005 Jul;8(1):49-59.

42.

Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling.

Hardwick JS, Yang Y, Zhang C, Shi B, McFall R, Koury EJ, Hill SL, Dai H, Wasserman R, Phillips RL, Weinstein EJ, Kohl NE, Severino ME, Lamb JR, Sepp-Lorenzino L.

Mol Cancer Ther. 2005 Mar;4(3):413-25.

43.

Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.

Bilodeau MT, Balitza AE, Koester TJ, Manley PJ, Rodman LD, Buser-Doepner C, Coll KE, Fernandes C, Gibbs JB, Heimbrook DC, Huckle WR, Kohl N, Lynch JJ, Mao X, McFall RC, McLoughlin D, Miller-Stein CM, Rickert KW, Sepp-Lorenzino L, Shipman JM, Subramanian R, Thomas KA, Wong BK, Yu S, Hartman GD.

J Med Chem. 2004 Dec 2;47(25):6363-72.

PMID:
15566305
44.

Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling.

Torrent M, Rickert K, Pan BS, Sepp-Lorenzino L.

J Mol Graph Model. 2004 Oct;23(2):153-65.

PMID:
15363457
45.

Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.

Wu Z, Fraley ME, Bilodeau MT, Kaufman ML, Tasber ES, Balitza AE, Hartman GD, Coll KE, Rickert K, Shipman J, Shi B, Sepp-Lorenzino L, Thomas KA.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):909-12.

PMID:
15012992
46.

A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo.

Sepp-Lorenzino L, Rands E, Mao X, Connolly B, Shipman J, Antanavage J, Hill S, Davis L, Beck S, Rickert K, Coll K, Ciecko P, Fraley M, Hoffman W, Hartman G, Heimbrook D, Gibbs J, Kohl N, Thomas K.

Cancer Res. 2004 Jan 15;64(2):751-6.

47.

Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.

Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI.

Prostate Cancer Prostatic Dis. 2001;4(1):33-43.

48.

The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells.

Sepp-Lorenzino L, Balog A, Su DS, Meng D, Timaul N, Scher HI, Danishefsky SJ, Rosen N.

Prostate Cancer Prostatic Dis. 1999 Jan;2(1):41-52.

49.

Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.

Sepp-Lorenzino L, Thomas KA.

Expert Opin Investig Drugs. 2002 Oct;11(10):1447-65. Review.

PMID:
12387705
50.

92nd Annual Meeting of the American Association for Cancer Research. 24-28 March, 2001, New Orleans, Louisiana, USA.

Buser C, Takaki T, Sepp-Lorenzino L.

Expert Opin Investig Drugs. 2001 Jun;10(6):1173-93.

PMID:
11785454

Supplemental Content

Loading ...
Support Center